|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
WHO007892438 |
| 003 |
DE-627 |
| 005 |
20230425175708.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
210913s2021 xx |||||o 00| ||eng c |
| 035 |
|
|
|a (DE-627)WHO007892438
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2021-001416-29-ES
|
| 035 |
|
|
|a (UBBS_Klinische_Studien_WHO)PREDEXACOV
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a High-dose dexamethasone treatment for SARS-COV-2
|b EARLY TREATMENT STRATEGY WITH HIGH-DOSE VERSUS STANDARD-DOSE DEXAMETHASONE IN PATIENTS WITH SARS-COV-2 PNEUMONIA (COVID-19). - PREDEXACOV-01
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 26-05-2021, Last updated: 2022-11-24
|
| 650 |
|
4 |
|a Medical Condition: Adult patients with SARS-CoV-2 infection (COVID19) requiring hospital admission for pneumonia. Who present pcr = 66 mg/L and =150 mg/L at inclusion or Pandemic score [13] on admission > 200 with pcr 9.7-149 mg/L at inclusion. WHO scale level 4 [14], with need for oxygen therapy in NG = 1 lpm to maintain saturation = 94%. ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
|
| 650 |
|
4 |
|a Study Type: Interventional
|
| 650 |
|
4 |
|a Phase: Phase 3
|
| 650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
| 650 |
|
4 |
|a 610
|
| 773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2021) vom: 07. Sept.
|
| 773 |
1 |
8 |
|g year:2021
|g day:07
|g month:09
|
| 856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001416-29
|z kostenfrei
|3 Volltext
|
| 912 |
|
|
|a GBV_CTG
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2021
|b 07
|c 09
|
Klinische Studie